Intra-Cellular Therapies (NASDAQ:ITCI) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI) in a research report report published on Saturday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Several other equities research analysts have also recently issued reports on the stock. Baird R W cut shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th. Mizuho lowered shares of Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and lowered their price target for the stock from $140.00 to $132.00 in a research report on Monday, February 24th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $132.00 price objective on shares of Intra-Cellular Therapies in a research note on Wednesday, April 2nd. Needham & Company LLC reissued a “hold” rating on shares of Intra-Cellular Therapies in a research note on Friday, February 21st. Finally, Canaccord Genuity Group lowered Intra-Cellular Therapies from a “buy” rating to a “hold” rating and upped their price target for the company from $119.00 to $132.00 in a research report on Friday, January 31st. Eleven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $106.23.

Intra-Cellular Therapies Stock Performance

Shares of Intra-Cellular Therapies stock opened at $131.87 on Friday. Intra-Cellular Therapies has a twelve month low of $64.09 and a twelve month high of $131.98. The firm has a market capitalization of $14.05 billion, a PE ratio of -151.57 and a beta of 0.69. The firm’s 50-day moving average price is $129.71 and its 200 day moving average price is $102.19.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). The firm had revenue of $199.22 million for the quarter, compared to analyst estimates of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. On average, sell-side analysts predict that Intra-Cellular Therapies will post -0.64 EPS for the current fiscal year.

Institutional Investors Weigh In On Intra-Cellular Therapies

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in shares of Intra-Cellular Therapies by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 9,721,360 shares of the biopharmaceutical company’s stock worth $811,928,000 after purchasing an additional 93,107 shares during the last quarter. Norges Bank purchased a new position in Intra-Cellular Therapies during the fourth quarter worth about $268,347,000. Invesco Ltd. increased its position in shares of Intra-Cellular Therapies by 2.9% during the fourth quarter. Invesco Ltd. now owns 3,077,174 shares of the biopharmaceutical company’s stock valued at $257,006,000 after acquiring an additional 87,582 shares during the last quarter. Deep Track Capital LP raised its stake in shares of Intra-Cellular Therapies by 24.9% in the 4th quarter. Deep Track Capital LP now owns 2,000,000 shares of the biopharmaceutical company’s stock valued at $167,040,000 after acquiring an additional 399,307 shares during the period. Finally, State Street Corp raised its stake in shares of Intra-Cellular Therapies by 3.1% in the 3rd quarter. State Street Corp now owns 1,858,915 shares of the biopharmaceutical company’s stock valued at $136,017,000 after acquiring an additional 56,664 shares during the period. Hedge funds and other institutional investors own 92.33% of the company’s stock.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.